TY - JOUR T1 - Risk of cancer was still increased over 2 years after stopping hormone therapy JF - Evidence Based Medicine JO - Evid Based Med SP - 142 LP - 142 DO - 10.1136/ebm.13.5.142 VL - 13 IS - 5 A2 - , Y1 - 2008/10/01 UR - http://ebm.bmj.com/content/13/5/142.abstract N2 - G HeissDr G Heiss, University of North Carolina School of Public Health, Chapel Hill, NC, USA; gerardo_heiss@unc.eduDesign:randomised placebo-controlled trial (Women’s Health Initiative [WHI] trial).Allocation concealment:{concealed}*.†Blinding:blinded (participants, clinicians, {data collectors, outcome assessors, and safety committee}*).†Setting:40 clinical centres in the USA.Patients:16 608 postmenopausal women 50–79 years of age with an intact uterus. 15 730 women (mean age 63 y) were included in the postintervention phase.Intervention:Conjugated equine oestrogen (CEO), 0.625 mg/day, plus medroxyprogesterone acetate (MPA), 2.5 mg/day (n = 8052), or placebo (n = 7678).Outcomes:included all-cause mortality; cardiovascular (CV) events (coronary heart disease [CHD], revascularisation, stroke, and thromboembolism); cancer (invasive breast, endometrial, colorectal, and all); fractures; … ER -